Drug intelligence / Profile preview

bengay

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

Bengay is a topical analgesic product used for temporary relief of minor muscle and joint pain. It contains three active ingredients (methyl salicylate, menthol, and camphor) that work as counterirritants by creating cooling and warming sensations on the skin. These sensations distract from pain in deeper tissues while menthol helps dilate blood vessels to improve blood flow to the affected area. The product is formulated to provide deep penetrating pain relief for conditions such as arthritis, backache, strains, bruises, and sprains.

Brand names: BENGAYBengay Ultra StrengthBengay Ultra Strength Non-Greasy
Other names: Baume BenguéBaume Analgésique Bengué

Targets

COXTRPA1 (Transient receptor potential cation channel subfamily A member 1)

Beyond the preview

Go deeper on bengay.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bengay.

Explore the full profile